In his role as Chief Medical Officer at Freenome, Lance leads all aspects of Freenome’s Clinical Development & Operations, Medical & Scientific Affairs, Quality, and Regulatory teams. Dr. Baldo is responsible for defining the strategy required to support Freenome's pipeline including clinical trials through commercial launch and post-marketing studies.
Prior to Freenome, Dr. Baldo was the Chief Medical Officer of Adaptive Biotechnologies and held numerous roles with the Roche Group and its affiliates, including Senior Vice President and Head of U.S. Medical Affairs of Genentech.
Lance serves on the Board of Advisors for the Werth Institute for Entrepreneurship and Innovation at the University of Connecticut, advising the school and young entrepreneurs with promising ideas for potential commercial development. Lance also supports Johns Hopkins Technology Ventures by helping assess promising university research, enabling discoveries to move from bench to the bedside. Lance holds an MD from the University of Connecticut School of Medicine and a BA in Biology from Johns Hopkins University.
Interview with Lance (published December 2022) https://mendelspod.com/podcasts/lance-baldo-freenome-their-approach-earl...